Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Improvements were also seen in complete response rates, duration of response, and time to next treatment
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Subscribe To Our Newsletter & Stay Updated
